Corcept Therapeutics
CORT
207 hedge funds and large institutions have $1.26B invested in Corcept Therapeutics in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 86 increasing their positions, 64 reducing their positions, and 34 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 64
1.21% more ownership
Funds ownership: 76.01% → 77.22% (+1.2%)
4% less funds holding
Funds holding: 215 → 207 (-8)
9% less capital invested
Capital invested by funds: $1.38B → $1.26B (-$121M)
21% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 34
46% less call options, than puts
Call options by funds: $6.35M | Put options by funds: $11.8M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$21.6M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$15.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$13.4M |
| 4 |
Morgan Stanley
New York
|
+$9.96M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$6.63M |
Top Sellers
CORT Hedge Fund Activity: Q3 2018 in Review
207 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2018, worth a combined $1.26B — down 8.8% from $1.38B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of CORT and 27 opened new positions — a net loss of 7 holders — while 64 trimmed existing stakes and 86 added.
The largest buyer was BlackRock, adding an estimated $21.6M. The largest seller was Acadian Asset Management, cutting an estimated $19M.
- 207 institutional investors held Corcept Therapeutics (CORT) as of Q3 2018, down from 215 in Q2 2018.
- Funds reported $1.26B of Corcept Therapeutics stock for Q3 2018, down 8.8% quarter-over-quarter.
- 27 funds opened new Corcept Therapeutics positions in Q3 2018 and 34 closed out, a net change of -7 holders.
- The largest Corcept Therapeutics buyer in Q3 2018 was BlackRock, an estimated $21.6M added.
- The largest Corcept Therapeutics seller in Q3 2018 was Acadian Asset Management, an estimated $19M sold.
Based on aggregated 13F filings for Q3 2018.